CASP3 and neoplasm: This therapeutic effect was associated with a significant reduction in proliferating Ki-67+ cells in lenvatinib-treated mice and a nonsignificant increase in active caspase-3+ apoptotic tumor cells in sorafenib-treated mice (Figures 3C, D).